Scoop
San Francisco, USA· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A biotech deploying a novel targeted protein degradation platform to drug challenging targets in oncology and neurology.
OncologyNeurodegenerative Diseases
Technology Platform
A targeted protein degradation platform focused on discovering novel molecular glues and heterobifunctional degraders that recruit E3 ubiquitin ligases to disease-causing proteins.
Opportunities
Potential to create first-in-class therapies for diseases driven by proteins that have eluded conventional drug discovery approaches.
Risk Factors
Platform risk associated with achieving tissue-specific degradation and managing potential on-target/off-tissue toxicities or 'hook effect' pharmacology.
Competitive Landscape
Operates in the hot but crowded targeted protein degradation field, requiring differentiation through novel biology or superior compound properties.